Invex Therapeutics (ASX:IXC) Price-to-Tangible-Book : 1.31 (As of Jun. 25, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Price-to-Tangible-Book?

As of today (2025-06-25), Invex Therapeutics's share price is A$0.094. Invex Therapeutics's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was A$0.07. Hence, Invex Therapeutics's Price to Tangible Book Ratio of today is 1.31.

The historical rank and industry rank for Invex Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

ASX:IXC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71 Med: 1.48 Max: 4.57
Current: 1.34

During the past 5 years, Invex Therapeutics's highest Price to Tangible Book Ratio was 4.57. The lowest was 0.71. And the median was 1.48.

ASX:IXC's Price-to-Tangible-Book is ranked better than
77.83% of 1200 companies
in the Biotechnology industry
Industry Median: 2.89 vs ASX:IXC: 1.34

A closely related ratio is called PB Ratio. As of today, Invex Therapeutics's share price is A$0.094. Invex Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2024 was A$0.07. Hence, Invex Therapeutics's P/B Ratio of today is 1.31.

Invex Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Invex Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Price-to-Tangible-Book Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Price-to-Tangible-Book

3.59

1.48

1.31

0.71

0.79

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial						1.66	0.71	1.16	0.79	0.92

Competitive Comparison of Invex Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Invex Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics Price-to-Tangible-Book Calculation

Invex Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	0.094	/	0.072
	=	1.31

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Invex Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.